Please assess the completion status of the following clinical trial:

Trial Title: Laser Removal of Age (Sun) Spots on Hands

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females or Males, 18 to 60 years of age (inclusive).~* Fitzpatrick Skin Type I - III (Appendix 2).~* Clinical diagnosis of benign solar lentigines of the hands.~* Presence of at least 5 lesions in the treatment area in diameters ranging from 1 to 8 mm.~* Has not used any prescription or over the counter topical creams (e.g., hydroquinone, and/or retinoids and/or corticosteroids) used in the treatment of pigmentation in the treatment area within the last 4 weeks.~* Willing to refrain from using any prescription or over the counter topical creams used for the treatment of pigmentation (e.g., hydroquinone, and/or retinoids and/or corticosteroids) in the treatment area during the study period.~* Must be able to read, understand and sign the Informed Consent Form.~* Willing and able to adhere to the treatment and follow-up schedule and before and after treatment care instructions.~* Willing to protect and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher in the treatment area starting up to 4 weeks before the treatment, every day for the duration of the study, including the follow-up period~* Willing to have digital photographs taken of the treatment area~* Agree not to undergo any other procedure(s) for the treatment of solar lentigines during the study.~* Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at last 3 months prior to enrollment and during the entire course of the study.~Exclusion Criteria:~* Participation in a study of another device of drug within 6 months prior to enrollment or during the study.~* Prior treatment of solar lentigines of the hands, e.g., with Q-Switched laser, IPL, Chemical peel, cryotherapy within 6 months of study participation.~* Having pre-malignant or malignant lesions (e.g., pigmented actinic keratosis, lentigo maligna \[12\], lentigo maligna melanoma), or history of a pre-malignant or malignant lesion in the treatment area.~* Subject shows signs of actinic bronzing or recent tanning in the treatment area, and unable/unlikely to refrain from tanning during the study.~* Skin abnormalities in the treatment area, e.g., cuts, scrapes, wounds, scars, large moles.~* Pregnant and/or breastfeeding.~* Having an infection, dermatitis or a rash in the treatment area.~* Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension~* Suffering from coagulation disorders or taking prescription anticoagulation medications.~* History of keloid scarring, hypertrophic scarring or of abnormal wound healing.~* History of immunosuppression/immune deficiency disorders or currently using immunosuppression medications.~* History of vitiligo or psoriasis.~* History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.~* History of seizure disorders due to light.~* Any use of medication that is known to increase sensitivity to light, such as tetracycline.~* History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.~* History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.~* Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.~* Current smoker or history of smoking within 2 years of study participation.~* As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.~* History of allergy to topical antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Picosecond QS Nd:YAG Laser (Type: EXPERIMENTAL): Laser Treatment with Investigational Device

Based on this trial design, predict the completion outcome and termination type (if applicable).